Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial

PCSK9 inhibitor valuation: A science-based review of the two recent models

(2018) Seth J. Baum et al.   CLINICAL CARDIOLOGY

Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome

(2018) Otavio Berwanger et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials

(2017) Konstantinos C Koskinas et al.   EUROPEAN HEART JOURNAL

Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study

(2017) Eliano P. Navarese et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome

(2016) Eliano P. Navarese et al.   ANNALS OF INTERNAL MEDICINE

Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries – Findings from the EUROASPIRE IV survey

(2016) Ž. Reiner et al.   ATHEROSCLEROSIS

Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms

(2016) Amirhossein Sahebkar et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

(2016) Alberico L. Catapano et al.   EUROPEAN HEART JOURNAL

Cross-talk between LOX-1 and PCSK9 in vascular tissues

(2015) Zufeng Ding et al.   CARDIOVASCULAR RESEARCH

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition

(2015) Nathalie Bergeron et al.   CIRCULATION

Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-ITCLINICAL PERSPECTIVES

(2015) Erin A. Bohula et al.   CIRCULATION

2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

(2015) Marco Roffi et al.   EUROPEAN HEART JOURNAL

Intracoronary imaging of coronary atherosclerosis: validation for diagnosis, prognosis and treatment

(2015) Konstantinos C. Koskinas et al.   EUROPEAN HEART JOURNAL

Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor

(2015) Rocco Romagnuolo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

(2015) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Proprotein convertase subtilisin/kexin type 9 expression is transiently up-regulated in the acute period of myocardial infarction in rat

(2015) Yan Zhang et al.   BMC Cardiovascular Disorders

2014 ESC/EACTS Guidelines on myocardial revascularization

(2014)   EUROPEAN HEART JOURNAL

Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin

(2014) Susan Kühnast et al.   JOURNAL OF LIPID RESEARCH

Effect of Atorvastatin Therapy on Fibrous Cap Thickness in Coronary Atherosclerotic Plaque as Assessed by Optical Coherence Tomography

(2014) Kenichi Komukai et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Plasma PCSK9 Levels Are Elevated with Acute Myocardial Infarction in Two Independent Retrospective Angiographic Studies

(2014) Naif A. M. Almontashiri et al.   PLoS One

Elevated Remnant Cholesterol Causes Both Low-Grade Inflammation and Ischemic Heart Disease, Whereas Elevated Low-Density Lipoprotein Cholesterol Causes Ischemic Heart Disease Without Inflammation

(2013) Anette Varbo et al.   CIRCULATION

High-Dose Atorvastatin on the Pharmacodynamic Effects of Double-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Interventions

(2013) Mario Leoncini et al.   JACC-Cardiovascular Interventions

Changes in Plaque Lipid Content After Short-Term Intensive Versus Standard Statin Therapy

(2013) Annapoorna S. Kini et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding

(2013) Udaya S. Tantry et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Mechanisms of Acute Coronary Syndromes and Their Implications for Therapy

(2013) Peter Libby   NEW ENGLAND JOURNAL OF MEDICINE

Impact of a High Loading Dose of Atorvastatin on Contrast-Induced Acute Kidney Injury

(2012) Cristina Quintavalle et al.   CIRCULATION

PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages

(2012) ZHIHAN TANG et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels

(2012) Clapton S. Dias et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels

(2011) Nicola Ferri et al.   ATHEROSCLEROSIS

PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax–caspase9–caspase3 pathway

(2011) Chun-Yan Wu et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

A Prospective Natural-History Study of Coronary Atherosclerosis

(2011) Gregg W. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of statins pretreatment on periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention: a meta-analysis

(2010) Feng Zhang et al.   ANNALS OF MEDICINE